{"title":"Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).","authors":"Hiroko Bando, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori E Nagai, Masaya Hattori, Kenichi Watanabe, Nobuko Tamura, Manabu Futamura, Kei Koizumi, Naoki Niikura, Tempei Miyaji, Yasuaki Muramatsu, Linghua Xu, Norikazu Masuda, Shigehira Saji","doi":"10.1007/s12282-025-01744-0","DOIUrl":"10.1007/s12282-025-01744-0","url":null,"abstract":"<p><strong>Objectives: </strong>To summarize descriptively health-related quality of life (HRQOL) and physical activity (PA) evaluated with a mobile application and wearable device among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 -) advanced breast cancer (ABC) treated with first- or second-line palbociclib plus endocrine therapy (ET) or ET alone.</p><p><strong>Methods: </strong>HRQOL was assessed with the EORTC QLQ-C30 at baseline and Day 15 of 6 treatment cycles (~ 24 weeks). PA metrics were averaged on a weekly basis for 24 weeks. Co-primary endpoints were mean change from baseline in Global Health Status (GHS) and sedentary time.</p><p><strong>Results: </strong>Ninety-nine patients were enrolled; 78 received palbociclib plus ET (mean age: 57.2 years; 75.6% initiated first-line treatment) and 21 received ET alone (mean age: 56.3 years; 90.5% initiated first-line treatment). Baseline mean GHS score was 60.9 in the palbociclib plus ET group and 64.3 in the ET alone group; mean changes from baseline to Day 15 of Cycle 6 were +4.8 and +2.9, respectively, and not deteriorated beyond the 10-point clinically significant threshold in either treatment group. Baseline mean sedentary time was 581 min/day in the palbociclib plus ET group and 513 min/day in the ET alone group; mean changes from baseline to Week 24 were -22 and -102 min/day, respectively.</p><p><strong>Conclusions: </strong>In this real-world study of women with HR+/HER2- ABC in Japan, neither palbociclib plus ET nor ET alone had any substantial detrimental impacts on HRQOL, according to patients' assessments recorded in a smartphone-based mobile application, and PA, as measured by a wearable device.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT04736576; registered, February 3, 2021.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1132-1143"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reevaluating ALND omission and its impact on abemaciclib eligibility and treatment decisions.","authors":"Shi-Yan Ren, Yi-Zhou Zhang","doi":"10.1007/s12282-025-01727-1","DOIUrl":"10.1007/s12282-025-01727-1","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1152-1153"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meiling Huang, Jian Zhang, Changjiao Yan, Rui Ling, Ting Wang
{"title":"KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway.","authors":"Meiling Huang, Jian Zhang, Changjiao Yan, Rui Ling, Ting Wang","doi":"10.1007/s12282-025-01737-z","DOIUrl":"10.1007/s12282-025-01737-z","url":null,"abstract":"<p><strong>Background: </strong>Kruppel-like factor 13 (KLF13) influences both immune system disorders and cancer progression, whereas the effects of KLF13 on the immune escape and breast cancer remain incompletely understood.</p><p><strong>Research design and methods: </strong>KLF13 expression was assessed in breast cancer tumor tissues. The roles of KLF13 in cell proliferation, migration, and immune evasion were assessed. RNA sequencing was used to identify the differentially expressed genes and signaling. Chip-seq and luciferase assays were performed to validate binding of KLF13 to its downstream genes. In vivo studies were conducted to confirm the function of KLF13. The mechanisms were elucidated using recovery assays.</p><p><strong>Results: </strong>KLF13 levels were higher in breast cancer tissue. Silencing KLF13 markedly diminished cell proliferation, migration, mammosphere formation, and immune evasion by suppressing the levels of HTRA1 and the Hedgehog signaling pathway. KLF13 overexpression potentiated breast cancer aggressiveness and enhanced immune evasion. Inhibiting KLF13 delayed development of cancer xenografts, as well as curtailing tumor growth, which were reversed by co-expression of HTRA1. Clinical relevance results suggested a positive correlation between KLF13, HTRA1 and density of CD8T cells in human breast cancer patients.</p><p><strong>Conclusions: </strong>KLF13 can serve as a tumor promoter in breast cancer by influencing HTRA1 and the Hedgehog signaling pathway.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1088-1101"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James E Fanning, Madeleine Givant, Angela Chen, Sarah Thomson, Elizabeth Tillotson, Aaron Fleishman, Kevin Donohoe, Dhruv Singhal
{"title":"Major anatomic variations of the lateral upper arm lymphatic pathway in a healthy female population.","authors":"James E Fanning, Madeleine Givant, Angela Chen, Sarah Thomson, Elizabeth Tillotson, Aaron Fleishman, Kevin Donohoe, Dhruv Singhal","doi":"10.1007/s12282-025-01742-2","DOIUrl":"10.1007/s12282-025-01742-2","url":null,"abstract":"<p><strong>Background: </strong>The lateral upper arm (LUA) pathway is a route of superficial lymphatic drainage that bypasses the axilla by draining to the deltopectoral, clavicular, and cervical lymph nodes. Despite the fact that anatomic variations of the LUA pathway have been implicated in breast cancer-related lymphedema (BCRL) risk after axillary lymph node dissection (ALND), the incidence of the LUA pathway variations in the healthy population has never been reported.</p><p><strong>Methods: </strong>Healthy female volunteers underwent bilateral lymphatic mapping of the upper extremities with indocyanine green (ICG) lymphography. ICG was injected in six standard sites in the hand/wrist and upper arm. Major anatomic variations of the LUA pathway were recorded including bundle phenotype (long, short, or absent), proximal visualization sites, and forearm pathway continuation to the long bundle phenotype.</p><p><strong>Results: </strong>90 arms of 45 volunteers were included. The LUA pathway was present in 99% of arms and a long-versus-short bundle phenotype was observed in 71% versus 28% of arms. When the long bundle was present, it was formed by continuity with the forearm posterior radial channel alone (47%), posterior ulnar channel alone (34%), or both channels (19%). The LUA pathway was traced proximally to the deltopectoral groove in 89% of arms and to the axilla in 11% of arms.</p><p><strong>Conclusions: </strong>We observed similar proportions of arms with long and short bundle phenotypes in comparison to our previous report of the LUA pathway in breast cancer patients with nodal disease. Defining the incidence of the LUA pathway with its variations in the general population is important as variations in this pathway may have implications for an individual's risk of developing BCRL.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1125-1131"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fu Ye, Xiaojing Chen, Yuchen Cao, Zhengneng You, Jianguo Lai
{"title":"The global, regional, and national disease burden of breast cancer attributable to behavioral risks from 1990 to 2021 and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021.","authors":"Fu Ye, Xiaojing Chen, Yuchen Cao, Zhengneng You, Jianguo Lai","doi":"10.1007/s12282-025-01771-x","DOIUrl":"https://doi.org/10.1007/s12282-025-01771-x","url":null,"abstract":"<p><strong>Background: </strong>Behavioral factors have been identified as crucial contributors to breast cancer (BC) risk, exhibiting distinct patterns across different regions, sexes, and age demographics. This study aims to analyze the spatiotemporal trends of behavior-related breast cancer (BRBC) at the global, regional, and national scales from 1990 to 2021, while also forecasting its future trajectory up to 2035.</p><p><strong>Methods: </strong>Utilizing the Global Burden of Disease 2021 data, we assessed BC mortality and disability-adjusted life years (DALYs) attributable to tobacco, alcohol, diet, and physical inactivity. Age-standardized rates (ASMR/ASDR) and estimated annual percentage change (EAPC) were calculated. Risk contributions, sociodemographic correlations, and population drivers were analyzed. Bayesian modeling projected future trends.</p><p><strong>Results: </strong>Global ASMR and ASDR declined slightly (EAPC: - 1.04/- 0.98), but absolute deaths rose 65.4% (125,701 in 2021). High-SDI regions showed declining rates, contrasting increases in low-middle SDI areas. Western Europe had the highest ASMR (7.43/100,000 in Nauru), while China reported maximal deaths (573,281). Dietary risks dominated BRBC burdens (48.2% deaths), followed by alcohol (21.6%), smoking (18.1%), and inactivity (12.1%). Alcohol-related risks exhibited the widest regional variability. Projections suggest ASMR declines by 2035 (8.16% female; 10% male), yet global deaths may reach 129,175 (female) and 2905 (male).</p><p><strong>Conclusions: </strong>This study first systematically analyzes behavioral risk factors' heterogeneous contributions to BC across socioeconomic levels and cultural contexts, revealing rising burdens, geographic disparities, resource inefficiencies, supporting precision interventions, and strategy translation.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cosmetic outcomes of rotation flap and suture scaffold for breast-conserving therapy in the lower quadrants.","authors":"Tomohiko Aihara, Noriko Aritake, Michiko Imamura, Masatsugu Okishiro, Tomoko Higuchi, Masao Aihara","doi":"10.1007/s12282-025-01767-7","DOIUrl":"https://doi.org/10.1007/s12282-025-01767-7","url":null,"abstract":"<p><strong>Background: </strong>Achieving good cosmetic outcomes after breast-conserving therapy (BCT) is crucial, particularly for tumors in the lower quadrant (BD region). This study evaluated the cosmetic outcomes of two oncoplastic techniques in patients with breast cancer in the BD region: rotation flap (RF) and suture scaffold (SS).</p><p><strong>Methods: </strong>This retrospective cohort study, conducted at a single institution, initially identified 45 consecutive female patients with primary unilateral breast cancer who underwent breast-conserving therapy using the RF (n = 22) or SS (n = 23) methods. After excluding those with tumors located outside the BD region and one patient lost to follow-up from each group, 25 patients (RF, n = 16; SS, n = 9) were included in the analysis. The cosmetic outcome at 6-12 months postoperatively was evaluated by two independent reviewers using the Harvard Breast Cosmesis Scale. Inter-rater agreement was quantified using quadratically weighted Cohen's κ values.</p><p><strong>Results: </strong>RF (n = 16) resulted in favorable cosmesis (81% excellent/good and 0% poor), while SS (n = 9) showed 56% excellent/good and 22% poor. The weighted kappa (κw) indicated a high inter-rater agreement for both RF (n = 16; κw = 0.897, p = 0.000331) and SS (n = 9; κw = 0.838, p = 0.0109). A comparison of these kappa coefficients revealed no statistically significant heterogeneity (p = 0.886; 95% CI for difference: -0.750-0.868). Complications were infrequent (RF, 6%; SS, 0%).</p><p><strong>Conclusion: </strong>In this single-center study, RF generally provided favorable cosmetic outcomes for BCT in the BD region. SS application resulted in more variable cosmetic results. RF may be a promising option for achieving good cosmesis at this anatomical location.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144986044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The association between neighborhood socioeconomic status and breast cancer incidence and mortality risk: a large-scale cohort studies systematic review and meta-analysis.","authors":"Faramarz Jalili, Mohammad Hajizadeh, Sanaz Mehrabani, Seyed Mojtaba Ghoreishy, Shirley Hodder","doi":"10.1007/s12282-025-01764-w","DOIUrl":"https://doi.org/10.1007/s12282-025-01764-w","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) remains one of the leading causes of cancer-related incidence and mortality globally, with growing evidence suggesting that neighborhood socioeconomic status (n-SES) can influence cancer incidence and survival. However, findings across studies remain inconsistent, and the extent to which n-SES impacts BC outcomes has not been comprehensively understood. A thorough systematic review and meta-analysis were conducted to assess the association of neighborhood socioeconomic status n-SES and BC incidence and mortality risk.</p><p><strong>Methods: </strong>A thorough investigation of existing literature was conducted by applying ISI Web of Science, PubMed/MEDLINE, and Scopus until June 08, 2025. Hazard ratios (HR), along with their respective 95% confidence intervals (CI), were integrated utilizing a random-effects model. A validated approach was utilized for assessing the quality of the studies and identification of publication bias, employing the Newcastle-Ottawa Scale for the assessment of quality, conducting subgroup analyses to identify potential sources of heterogeneity, and applying Egger's regression to detect publication bias and perform sensitivity analyses.</p><p><strong>Results: </strong>A total of 17 studies with 779,352 adult subjects were found. The results revealed no association of significance among disadvantaged n-SES and BC incidence risk (HR = 1.19; 95% CI 0.86, 1.65; I<sup>2</sup> = 97.7%; p = 0.300; n = 10). However, the subgroup analysis reveals an association of significance among disadvantaged n-SES status and a decreased BC incidence risk in case-control studies (vs. cohort studies) (HR = 0.81; 95% CI 0.72, 0.92; I<sup>2</sup> = 0.0%; p = 0.001; n = 2) and for the luminal A cancer sub-type (HR = 0.84; 95% CI 0.73, 0.91; I<sup>2</sup> = 29.3%; p = 0.012; n = 3). In contrast, the subgroup analysis revealed an significance association between disadvantaged n-SES status and an increased BC incidence for HER2 + (HR = 1.46; 95% CI 1.14, 1.78; I<sup>2</sup> = 0.0%; p = 0.002; n = 2) or the triple-negative cancer sub-type (HR = 1.39; 95% CI 1.19, 1.69; I<sup>2</sup> = 41.1%; p < 0.001; n = 4). The results also suggest a significant association between disadvantaged n-SES and a higher BC mortality risk (HR = 1.32; 95% CI 1.16, 1.51; I<sup>2</sup> = 76.4%; p < 0.001; n = 8). Sensitivity analyses and an evaluation of publication bias revealed no significant association with BC incidence or mortality risk.</p><p><strong>Conclusion: </strong>Disadvantaged n-SES is identified as a significant element to higher death rates related to BC. By understanding the root causes of inequalities in BC incidence and mortality across different socioeconomic environments, targeted interventions can be tailored to meet the specific needs of vulnerable individuals, ultimately leading toward improved BC outcomes for those at greatest risk.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk factors for early-onset radiodermatitis in patients with locally advanced breast cancer: a comparative analysis of volumetric modulated arc therapy and intensity-modulated radiotherapy.","authors":"Chih-Chieh Chang, Po-Wei Huang, Jang-Chun Lin, Jo-Ting Tsai, Shih-Ming Hsu","doi":"10.1007/s12282-025-01762-y","DOIUrl":"https://doi.org/10.1007/s12282-025-01762-y","url":null,"abstract":"<p><strong>Background: </strong>Radiodermatitis is the predominant acute toxicity in locally advanced breast cancer (BC) radiotherapy. Early-onset radiodermatitis substantially increases the risk of high-grade injury and potential treatment interruption. This study aimed to identify risk factors for early-onset radiodermatitis by analyzing patient characteristics and dose-distribution profiles from step-and-shoot intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT).</p><p><strong>Methods: </strong>This retrospective analysis included 128 women with locally advanced unilateral BC who received postoperative IMRT or VMAT. Patient demographics, treatment parameters, and three-dimensional dose-volume metrics were extracted. Early-onset radiodermatitis was defined as CTCAE v5.0 grade ≥ 1 developing before the 20th treatment fraction. Univariable and multivariable logistic regression identified independent risk factors, and dosimetric variables were compared between IMRT and VMAT.</p><p><strong>Results: </strong>Early-onset radiodermatitis was observed in 35 of 128 patients (27.3%). Four independent predictors were identified: treatment technique (IMRT versus VMAT: odds ratio [OR] 4.25; 95% confidence interval [CI] 1.30-13.94; p = 0.017), left-sided irradiation (OR 20.98; 95% CI 2.39-184.27; p = 0.006), heart V<sub>5</sub> (OR 0.85 per 1% increase; 95% CI 0.74-0.97; p = 0.012), and PTV<sub>Breast</sub> volume (OR 1.002 per cc; 95% CI 1.000-1.004; p = 0.023). VMAT provided superior target coverage and reduced high-dose exposure to the heart and ipsilateral lung (V<sub>40</sub>), whereas IMRT better limited low-dose spill to the contralateral breast and lung and to the ipsilateral lung (V<sub>5</sub>).</p><p><strong>Conclusions: </strong>IMRT, left-sided irradiation, low heart V<sub>5</sub>, and large PTV<sub>Breast</sub> volume were independent risk factors for early-onset radiodermatitis. Awareness of these factors can guide prophylactic skin care and adaptive planning. While VMAT provides advantages in target coverage and cardiac/high-dose lung sparing against IMRT's superior control of low-dose exposure to normal tissues.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study.","authors":"Chitose Kawamura, Krishnan Bhaskaran, Takaaki Konishi, Yasuaki Sagara, Hiroko Bando, Tomohiro Shinozaki, Shuko Nojiri, Motohiko Adomi, Angel Y S Wong, Nanako Tamiya, Masao Iwagami","doi":"10.1007/s12282-025-01769-5","DOIUrl":"https://doi.org/10.1007/s12282-025-01769-5","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) survivors may have an increased risk of endometrial cancer due to shared risk factors and tamoxifen use. However, the risk among women in Japan and that for each endocrine therapy regimen remains unknown when comparing BC survivors to women without BC.</p><p><strong>Methods: </strong>We conducted a matched-cohort study using the JMDC claims database, covering company employees and their family members in Japan. Between January 2005 and December 2019, women aged 18-74 years with BC were matched to women without BC in a 1:4 ratio by age and database entry timing. Endometrial cancer risk was compared using stratified Cox regression. In addition, starting the follow-up at one year after matching, we assessed risk by endocrine treatment (tamoxifen, aromatase inhibitor [AI], and no endocrine therapy) using unstratified Cox regression.</p><p><strong>Results: </strong>Among 23,729 BC survivors and 95,659 matched women (median age, 49.5 years), there were 56 vs 40 endometrial cancer cases (0.73 vs 0.13 cases/1,000 person-years, respectively), with adjusted hazard ratios of 7.71 (95% confidence interval 4.56-13.0). In the analysis by endocrine treatment, tamoxifen (n = 9,183; median 46.3 years), AI (n = 4,582; 58.1 years), and no endocrine therapy (n = 5,763; 49.4 years) cases were 26, 5, and 10 (0.92, 0.43, and 0.61 cases/1,000 person-years, respectively), and the adjusted hazard ratios were 5.67 (3.20-10.0), 2.17 (0.79-5.95), and 3.56 (1.66-7.65), respectively, compared to women without BC.</p><p><strong>Conclusions: </strong>BC survivors in Japan had an increased risk of endometrial cancer compared to women without BC. The risk was higher in women prescribed tamoxifen and those with no endocrine therapy.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Patient satisfaction on prescription refill systems for breast cancer patients in Japan using a digital self-administered survey.","authors":"Masanori Oshi, Mahato Sasamoto, Maya Isoda, Kei Kawashima, Yuka Matsubara, Keiko Ide, Kazutaka Narui, Nobuyasu Suganuma, Akimitsu Yamada, Ichiro Ota, Takeshi Asami, Aya Saito, Takashi Ishikawa, Itaru Endo","doi":"10.1007/s12282-025-01761-z","DOIUrl":"https://doi.org/10.1007/s12282-025-01761-z","url":null,"abstract":"<p><strong>Background: </strong>Time toxicity in breast cancer refers to the time burden patients face from treatments, hospital visits, and managing side effects. As survival improves, attention has shifted to the impact of time spent on care. For those receiving long-term endocrine therapy, visiting hospital and waiting time for clinic affect their daily life. Thus, reducing time toxicity is essential to improve quality of life alongside survival outcomes.</p><p><strong>Methods: </strong>This study surveyed postoperative breast cancer patients requiring hormonal therapy, who attended Yokohama City University Hospital from August 2023 to July 2024, using a digital self-administered survey to assess prescription refills. The Hospital Anxiety and Depression Scale and the original questionnaire were used to compare changes in status of patients before and after the introduction of prescription refills.</p><p><strong>Results: </strong>A comparison of outpatient visits before and after prescription refills revealed a decreasing trend in visit frequency. Patient satisfaction showed a significant improvement, with patients giving higher ratings after prescription refills were introduced. The proportion of patients experiencing shorter waits increased, with 49% reporting a reduction in waiting times. Anxiety about extended visit intervals decreased, with only 1% of patients reporting increased anxiety. Notably, patient satisfaction with prescription refills remained high across various postoperative durations and age groups. Approximately 70% of patients expressed a desire to continue using prescription refills, indicating overall positive reception regardless of age or postoperative period.</p><p><strong>Conclusion: </strong>The introduction of prescription refills led to a reduction in outpatient visits and improvements in patient satisfaction and perceived waiting times. Prescription refills, recently introduced in Japan, are not yet widely recognized but may become a valuable tool for breast cancer patients and healthcare providers. Further research is required to assess the impact of the prescription refills on patient outcomes.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}